JAK2 and myeloproliferative disorder: The present study allows: i) to quantify the induction of hematopoiesis induced by iPS generated from MPN patients with either heterozygous or homozygous JAK2V617F mutation, ii) to investigate how JAK2 signaling intensity generates disease heterogeneity and iii) to develop new tools to test small molecules.